

## BioMarin's CANOPY-NS, TS, SHOX-D-2 Clinical Development Program: An Update for the Community

BioMarin is pleased to update the community regarding the launch of our clinical trial program, CANOPY NS, TS, SHOX-D-2 exploring the use of vosoritide in Noonan syndrome, Turner syndrome, and SHOX deficiency. BioMarin's vosoritide, for Noonan syndrome, Turner syndrome, and SHOX deficiency, has not been approved for use; it is in ongoing clinical trials evaluating its safety and efficacy.

### Clinical Trial Overview

BioMarin's vosoritide is currently being studied in children who have been diagnosed with Noonan syndrome, Turner syndrome, and SHOX deficiency. CANOPY NS, TS, SHOX-D-2 (111-211) is a basket Phase 2 interventional study of vosoritide. The purpose of this basket study in children with Noonan syndrome, Turner syndrome, and SHOX deficiency is to evaluate the effect of 3 doses of vosoritide versus human growth hormone (hGH) on growth as measured by annual growth velocity (AGV) after 6 months of treatment. This study is currently active in the United States with the goal of enrolling 72 participants. BioMarin's vosoritide, for Noonan syndrome, Turner syndrome, and SHOX deficiency, has not been approved for use.

BioMarin extends its sincere gratitude to our investigators and those who may take part in this study.



#### For additional information:

- Visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and type in the study code "CANOPY-NTS-D-2"
- For inquiries or to provide feedback from advocacy organizations, please contact: [patientadvocacy@bmrn.com](mailto:patientadvocacy@bmrn.com)
- Contact BioMarin Medical Information at [medinfo@bmrn.com](mailto:medinfo@bmrn.com) or toll free at 1-800-983-4587